Article Figures & Data
Figures
- FIG. 1.
The effect of amprenavir on HIVIIIB replication is shown when continuous-infusion (▴), BID (•), TID (+), and no-drug (▪) regimens are followed.
- FIG. 2.
The effect of amprenavir on HIV suppression as a function of time > EC95 is shown for continuous-infusion, BID, and TID regimens.
- FIG. 3.
The plot of observed versus predicted amprenavir concentrations in plasma after population pharmacokinetic modeling and MAP-Bayes estimation is shown.
- FIG. 4.
(A) The target attainment rate for a given EC50 for amprenavir and ritonavir at doses of 600 and 100 mg, respectively, is shown with a target of more than four times the EC50. (B) The target attainment rate for a given EC50 for amprenavir and ritonavir at does of 600 and 100 mg, respectively, is shown with a target Cmin/EC50 ratio of 5.
Tables
- TABLE 1.
Characteristics of study group
Characteristic Value for: Participants in pharmacokinetics analysis (n = 12) Trial participants (n = 13a) Gender Male 9 9 Female 3 4 Race Caucasian 5 5 African-American 4 5 Hispanic 3 3 Age (yr) Mean 38.2 37.3 Range 31.1-47.7 25.9-47.7 Wt (kg) Mean 83.9 81.1 Range 66.4-106.9 50-106.9 Baseline CD4-cell count (no. of cells/mm3) Mean 292 281 Range 42-618 42-618 Baseline viral load (no. of log10 copies/ml) Mean 4.24 4.25 Range 3.44-5.65 3.44-5.65 ↵ a One patient was excluded from the pharmacokinetic analysis.
- TABLE 2.
Pharmacokinetic parametersa
Determination kel (h−1) Ka (h−1) V1 (liter) Kcp (h−1) Kpc (h−1) Time lag (h) Mean 0.179 16.78 100.6 5.049 12.42 0.616 Median 0.180 8.550 92.50 0.720 0.386 0.470 SD 0.0614 15.48 46.12 8.967 17.55 0.300 ↵ a k el, elimination rate constant; Ka, absorption rate constant; V1, volume of distribution in the central compartment; Kcp, intercompartmental rate constant from the central to the peripheral compartment; Kpc, intercompartmental rate constant from the peripheral to the central compartment; time lag, lag time to absorption.
